Tillkännagivande • Jun 08
Olink® Target 48 Immune Surveillance Panel – the Next Frontier in Immune Biomarker Profiling with Absolute Confidence Olink Holding AB (publ) announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research. Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1µL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2µL of sample. This represents a powerful new tool for identifying protein signatures across a range of important therapeutic areas including inflammation, immune response, immuno-oncology and infectious diseases. Developed using Olink’s proven PEA™ technology, Olink Target 48 Immune Surveillance delivers complete confidence with transparent quality control. In addition to internal quality control and validation, Olink works closely with the research community to further test, validate, and improve the performance of products. Tillkännagivande • May 31
Researchers Use Olink®? Explore to Identify Circulating Proteins That May Give Cancer Warning 7 Years Before Diagnosis Olink Holding AB (publ) reported the publication of a landmark study using the Olink Explore platform to identify proteins in the blood that may provide a 7-year warning for various cancers. The findings, published in Nature Communications, illustrate the tremendous potential of proteomics to revolutionize cancer detection, allowing for intervention at much earlier stages, potentially leading to better treatment outcomes and even prevention. Early Detection - A Game Changer. In the groundbreaking work, conducted by Oxford Population Health and funded by Cancer Research UK, researchers describe how they used Olink's next-generation proteomics platform to analyze blood samples from over 44,000 individuals. They were able to pinpoint 371 proteins linked to 19 different cancers, including 107 proteins that were detectable in individuals more than seven years before cancer diagnosis. Olink - Unlocking the Power of Proteomics. Olink's innovative proteomics solution played a pivotal role in the Oxford Population Health research. Owing to its scalability and specificity, researchers were able to accurately analyze a huge number of proteins across tens of thousands of samples, uncovering crucial information hidden within the human body's complex protein makeup. This study is a powerful example of how proteomics is driving a new era of discovery. Details of the study will be presented as part of the Olink Proteomics Corporate Symposium at European Society of Human Genetics conference in Berlin on June 1 - 4. Dr Atkins, alongside other speakers, will describe how the UK Biobank Pharma Proteomics Project, the world's largest proteomics study backed by 13 leading pharmaceutical companies, analyzed samples from over 54,000 participants and identified over 20,000 novel genetic associations with plasma protein levels, finally helping to bridge the gap between genetics and disease pathology. The Road ahead - Refining and Developing Solutions. While these findings hold immense promise for the future of cancer management, the research team emphasized the need for further investigation. Understanding the specific role these proteins play in cancer development and identifying the most reliable ones for testing are crucial next steps. Reported Earnings • May 14
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2024 results: US$0.13 loss per share (further deteriorated from US$0.11 loss in 1Q 2023). Revenue: US$28.8m (up 4.7% from 1Q 2023). Net loss: US$16.1m (loss widened 15% from 1Q 2023). Revenue missed analyst estimates by 4.9%. Earnings per share (EPS) exceeded analyst estimates by 9.3%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Breakeven Date Change • Mar 26
Forecast breakeven date pushed back to 2025 The 4 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 52% to 2024. The company is expected to make a profit of US$12.4m in 2025. Average annual earnings growth of 61% is required to achieve expected profit on schedule. Reported Earnings • Mar 26
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: US$0.25 loss per share (further deteriorated from US$0.11 loss in FY 2022). Revenue: US$169.6m (up 21% from FY 2022). Net loss: US$31.6m (loss widened 146% from FY 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) also missed analyst estimates. Revenue is forecast to grow 17% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Tillkännagivande • Mar 09
Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024 Olink Holding AB (publ), Annual General Meeting, Apr 19, 2024. Tillkännagivande • Jan 18
Olink Holding AB Announces Promotion of Maria Liminga Björk to Chief Research and Development Officer On January 16, 2024, Olink Holding AB announced the promotion of Maria Liminga Björk (PhD) to Chief Research and Development Officer. Ms. Björk joined Olink as Vice President of Research and Development in March 2023. Prior to her role at Olink, Ms. Björk served as Director of BioProcess Research and Development at Cytiva, a Danaher Corporation subsidiary, from 2020 to 2023. In this role, Ms. Björk led an organization responsible for development of novel purification solutions for the biopharmaceutical industry. From 2016 to 2020, Ms. Björk directed the Resin and Ligand Department at GE HealthCare Technologies Inc. (d/b/a GE HealthCare). Ms. Björk holds a Masters in Pharmaceutical Biosciences and a PhD in Biochemical Pharmacology from Uppsala University. Reported Earnings • Nov 17
Third quarter 2023 earnings: EPS and revenues exceed analyst expectations Third quarter 2023 results: US$0.01 loss per share. Revenue: US$44.2m (up 39% from 3Q 2022). Net loss: US$1.82m (loss widened 41% from 3Q 2022). Revenue exceeded analyst estimates by 3.4%. Earnings per share (EPS) also surpassed analyst estimates by 88%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Life Sciences industry in the US. Tillkännagivande • Oct 26
Olink Holding AB (publ) to Report Q3, 2023 Results on Nov 15, 2023 Olink Holding AB (publ) announced that they will report Q3, 2023 results Pre-Market on Nov 15, 2023 New Risk • Oct 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 19% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risk Shareholders have been diluted in the past year (4.4% increase in shares outstanding). Tillkännagivande • Oct 07
Olink Holding AB (publ) Demonstrates the Power of the Olink Explore Platform for Driving Impactful Proteogenomic Studies At the Population Scale Olink Holding AB (publ) reported the publication of three articles in the prestigious scientific journal, Nature, that demonstrate the power of the Olink Explore platform for driving impactful proteogenomic studies at the population scale. The studies each used data generated from the UK Biobank Pharma Proteomics Project (UKB-PPP), whereby 13 pharmaceutical companies generated new proteomic data from accessing the UK Biobank. Using the Olink Explore platform, researchers measured around 3,000 proteins in more than 54,000 UKB participant samples. By combining genomic and proteomic analyses at an unprecedented scale, a wealth of new information is available on the genetic effects on protein expression and phenotypic outcomes. The findings illustrate the immense value of proteogenomics in elucidating biological mechanisms, identifying actionable new biomarkers, and accelerating drug development efforts. The paper by Sun et al. from the UKB-PPP consortium provides the first detailed summary of the data, accompanied by downstream GWAS-based proteogenomic analyses, protein quantitative trait loci (pQTL) mapping, cross- section disease associations, and proteomic predictions of demographic factors and physiological functions. By uncovering over 14,000 genetic associations with protein expression levels, 81% of which are novel, their findings from this landmark paper clearly show the importance of high-throughput protein measurements for identifying important biological pathways and their impact on health. A second paper by Dhindsa et al., primarily authored by consortium members from AstraZeneca, used the dataset described in the paper to study genetic associations of rare protein-coding variants with protein expression. The results shed light on the vital role of rare variants in plasma protein level variation and biological outcomes, further underscoring the crucial need for large-scale proteogenomic studies to enable such discoveries. The third article by Eldjarn et al. describes a study where the Olink-generated results in the UKB-PPP dataset were compared to the proteogenomic analysis of a large Icelandic population cohort using an aptamer-based technology. While both platforms identified a large number of genetic associations with protein levels, a significantly higher proportion of the proteins measured using Olink (72% versus 43% when using the aptamer-based technology) had cis-pQTLs associated with them, providing strong genetic corroboration for superior specificity of the Olink assays. Furthermore, median CV ratios were lower for the Olink assays, indicating they were more precise on average. Tillkännagivande • Sep 19
Olink Holding AB (Publ) Announces the Introduction of Olink(R) Target 48 Mouse Cytokine Panel Olink Holding AB (publ) announced the introduction of Olink(R) Target 48 Mouse Cytokine Panel, a validated multiplexed protein panel that offers a detailed view of the murine immune system, enabling in-depth disease modelling, longitudinal studies and translational research. The Olink Target 48 Mouse Cytokine Panel represents a new standard in immunoassays giving researchers the ability to accurately measure 43 carefully selected immune-related proteins using as little as 1ul of sample volume. Offering multiplexing with unparalleled specificity combined with high sensitivity, the T48 Mouse Cytokine panel unlocks true longitudinal studies over multiple timepoints in individual mice. The transparent validation and streamlined workflow maintains the exceptional standards of performance that users have come to expect from Olink. The addition of a targeted mouse panel with absolute quantification capabilities adds to Olink`s broad portfolio of proteomics solutions. From pre-clinical mouse models to human clinical applications, Olink provides solutions encompassing all stages of drug development and disease modelling. The Olink Target 48 Mouse Cytokine Panel was designed to deliver an in-depth view of cytokine signalling and inflammatory pathways for pre-clinical and translational research. It can be utilized across key application areas to deepen current understanding of molecular pathways involved in the disease initiation and progression. Olink Target 48 Mouse Cytokine Panel is fully compatible with the Olink(R) Signature Q100, a high performance, auto-calibrated instrument for data readout that facilitates unattended operation. Work efficiency is further increased by the streamlined assay workflow with minimal hands-on time. Recent Insider Transactions Derivative • Aug 20
Chief Scientific Officer notifies of intention to sell stock Ida Grundberg intends to sell 35k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of August. If the sale is conducted around the recent share price of US$16.89, it would amount to US$591k. Since December 2022, Ida has owned 653.86k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Breakeven Date Change • Aug 13
Forecast breakeven date pushed back to 2025 The 5 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$50.5m in 2025. Average annual earnings growth of 54% is required to achieve expected profit on schedule. Reported Earnings • Aug 10
Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Second quarter 2023 results: US$0.067 loss per share (further deteriorated from US$0.04 loss in 2Q 2022). Revenue: US$29.4m (up 7.0% from 2Q 2022). Net loss: US$8.27m (loss widened 72% from 2Q 2022). Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 38%. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US. Tillkännagivande • Aug 10
Olink Holding AB (Publ) Reiterates Revenue Guidance for the Full Year 2023 Olink Holding AB (publ) reiterated revenue guidance for the full year 2023. For the year, company expects revenue guidance of $192 million to $200 million. Tillkännagivande • Jul 14
Olink Holding AB (publ) to Report Q2, 2023 Results on Aug 09, 2023 Olink Holding AB (publ) announced that they will report Q2, 2023 results Pre-Market on Aug 09, 2023 Tillkännagivande • Jul 13
Olink Holding AB (Publ) Announces the Introduction of Olink(R) Explore Ht Olink Holding AB (publ) announced the introduction of Olink(R) Explore HT, a transformational solution for high-throughput proteomics delivering unmatched specificity, scalability, and workflow simplicity. Olink Explore HT represents a significant advancement in next generation proteomics, allowing scientists to accurately measure over 5,300 proteins using only 2ul of sample with a completely reimagined and streamlined workflow, including a highly automated data analysis platform. In addition to delivering over 80% more unique protein assays than the previous generation product, Olink Explore HT increases sample throughput by 4X and data output by 7X with a >30% reduction in cost per data point and >20% reduction in workflow processing cost. Importantly, these innovations substantially reduce the environmental footprint with a 6-fold decrease in components and 10-fold reduction in boxes. Olink Explore HT was designed to unlock the immense value of proteomics at any scale and advance multi-omic research. It can be utilized across a wide range of therapeutic areas to deepen current understanding of molecular pathways involved in the development, progression, and outcome of disease. Olink Explore HT will also empower new discoveries in drug development, from target discovery based on identification of proteins causal in disease, to actionable insights into mode of action studies and repurposing of therapeutics from reinterrogation of existing samples from clinical trials. Buying Opportunity • Jun 16
Now 23% undervalued after recent price drop Over the last 90 days, the stock is down 16%. The fair value is estimated to be US$24.48, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last year. Earnings per share has grown by 60%. Revenue is forecast to grow by 47% in a year. Earnings is forecast to grow by 31% in the next year. Buying Opportunity • May 31
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be US$24.61, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 39% over the last year. Earnings per share has grown by 60%. Revenue is forecast to grow by 48% in a year. Earnings is forecast to grow by 31% in the next year. Major Estimate Revision • May 20
Consensus EPS estimates fall by 18% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.13 to -US$0.153 per share. Revenue forecast of US$196.5m unchanged since last update. Life Sciences industry in the US expected to see average net income growth of 7.7% next year. Consensus price target of US$25.20 unchanged from last update. Share price fell 3.3% to US$20.79 over the past week. Major Estimate Revision • May 18
Consensus EPS estimates fall by 18% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.13 to -US$0.153 per share. Revenue forecast unchanged at US$196.5m. Life Sciences industry in the US expected to see average net income growth of 6.2% next year. Consensus price target up from US$24.60 to US$25.20. Share price fell 3.8% to US$20.76 over the past week. Price Target Changed • May 13
Price target increased by 8.7% to US$25.00 Up from US$23.00, the current price target is an average from 5 analysts. New target price is 16% above last closing price of US$21.51. Stock is up 82% over the past year. The company is forecast to post a net loss per share of US$0.15 next year compared to a net loss per share of US$0.11 last year. Tillkännagivande • May 12
Olink Holding AB (Publ) Provides Earnings Guidance for the Year 2023 Olink Holding AB (publ) provided earnings guidance for the year 2023. For the year, the company expects full year reported revenue to be in the range of $192 million to $200 million, representing growth of approximately 37% to 43% on a reported basis, and growth of approximately 38% to 44% on a constant currency basis. Reported Earnings • May 12
First quarter 2023 earnings released: US$0.11 loss per share (vs US$0.10 loss in 1Q 2022) First quarter 2023 results: US$0.11 loss per share (further deteriorated from US$0.10 loss in 1Q 2022). Revenue: US$27.5m (up 21% from 1Q 2022). Net loss: US$14.0m (loss widened 15% from 1Q 2022). Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Life Sciences industry in the US. Reported Earnings • Mar 29
Full year 2022 earnings: Revenues in line with analyst expectations Full year 2022 results: Revenue: US$139.8m (up 47% from FY 2021). Net loss: US$12.9m (loss narrowed 70% from FY 2021). Revenue was in line with analyst estimates. Revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Major Estimate Revision • Feb 28
Consensus estimates of losses per share improve by 21% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from US$194.6m to US$196.6m. EPS estimate increased from -US$0.165 per share to -US$0.13 per share. Life Sciences industry in the US expected to see average net income growth of 1.3% next year. Consensus price target up from US$23.00 to US$24.60. Share price fell 2.6% to US$21.93 over the past week. Reported Earnings • Feb 22
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: US$0.11 loss per share (improved from US$0.43 loss in FY 2021). Revenue: US$139.8m (up 47% from FY 2021). Net loss: US$12.9m (loss narrowed 70% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 27%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 6.4% growth forecast for the Life Sciences industry in the US. Price Target Changed • Dec 15
Price target increased to US$22.00 Up from US$19.00, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of US$22.90. Stock is up 17% over the past year. The company is forecast to post a net loss per share of US$0.15 next year compared to a net loss per share of US$0.43 last year. Reported Earnings • Nov 16
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.011 loss per share (improved from US$0.046 loss in 3Q 2021). Revenue: US$31.8m (up 59% from 3Q 2021). Net loss: US$1.29m (loss narrowed 77% from 3Q 2021). Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates by 87%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Board Change • Nov 16
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 12
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Third quarter 2022 results: US$0.01 loss per share (improved from US$0.046 loss in 3Q 2021). Revenue: US$31.8m (up 59% from 3Q 2021). Net loss: US$1.29m (loss narrowed 77% from 3Q 2021). Revenue exceeded analyst estimates by 9.7%. Earnings per share (EPS) also surpassed analyst estimates by 87%. Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Major Estimate Revision • Oct 14
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$0.24 to -US$0.21 per share. Revenue forecast unchanged from US$141.7m at last update. Life Sciences industry in the US expected to see average net income growth of 5.5% next year. Consensus price target of US$19.00 unchanged from last update. Share price rose 10% to US$15.60 over the past week. Major Estimate Revision • Aug 18
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 losses forecast to reduce from -US$0.37 to -US$0.24 per share. Revenue forecast steady at US$141.5m. Life Sciences industry in the US expected to see average net income growth of 5.4% next year. Consensus price target broadly unchanged at US$19.00. Share price rose 2.0% to US$17.48 over the past week. Reported Earnings • Aug 12
Second quarter 2022 earnings: EPS and revenues exceed analyst expectations Second quarter 2022 results: US$0.04 loss per share (up from US$0.089 loss in 2Q 2021). Revenue: US$27.5m (up 56% from 2Q 2021). Net loss: US$4.82m (loss narrowed 55% from 2Q 2021). Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) also surpassed analyst estimates by 71%. Over the next year, revenue is forecast to grow 51%, compared to a 4.0% growth forecast for the industry in the US. Major Estimate Revision • May 19
Consensus forecasts updated The consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.23 to -US$0.37 per share. Revenue forecast unchanged at US$141.6m. Life Sciences industry in the US expected to see average net income growth of 7.3% next year. Consensus price target down from US$26.25 to US$18.33. Share price rose 3.6% to US$10.79 over the past week. Reported Earnings • May 13
First quarter 2022 earnings: EPS and revenues exceed analyst expectations First quarter 2022 results: US$0.10 loss per share (up from US$0.37 loss in 1Q 2021). Revenue: US$22.7m (up 66% from 1Q 2021). Net loss: US$12.2m (loss narrowed 15% from 1Q 2021). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 29%. Over the next year, revenue is forecast to grow 51%, compared to a 6.4% growth forecast for the industry in the US. Breakeven Date Change • May 07
Forecast breakeven date moved forward to 2023 The 3 analysts covering Olink Holding previously expected the company to break even in 2024. New consensus forecast suggests losses will reduce by 47% to 2022. The company is expected to make a profit of US$2.50m in 2023. Average annual earnings growth of 98% is required to achieve expected profit on schedule. Board Change • Apr 27
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. 2 experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Breakeven Date Change • Apr 13
Forecast to breakeven in 2024 The 4 analysts covering Olink Holding expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 68% per year to 2023. The company is expected to make a profit of US$21.7m in 2024. Average annual earnings growth of 91% is required to achieve expected profit on schedule. Major Estimate Revision • Feb 21
Consensus EPS estimates fall by 68% The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$145.2m to US$141.7m. Losses expected to increase from US$0.14 per share to US$0.23. Life Sciences industry in the US expected to see average net income growth of 9.1% next year. Consensus price target down from US$35.25 to US$29.75. Share price fell 16% to US$16.12 over the past week. Reported Earnings • Feb 16
Full year 2021 earnings: Revenues exceed analyst expectations Full year 2021 results: Revenue: US$95.0m (up 76% from FY 2020). Net loss: US$38.3m (loss widened 79% from FY 2020). Revenue exceeded analyst estimates by 2.5%. Over the next year, revenue is forecast to grow 50%, compared to a 10% growth forecast for the pharmaceuticals industry in the US. Board Change • Jan 01
High number of new and inexperienced directors There are 8 new directors who have joined the board in the last 3 years. The company's board is composed of: 8 new directors. No experienced directors. No highly experienced directors. Director Tommi Unkuri is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 13
Third quarter 2021 earnings released: US$0.046 loss per share The company reported a soft third quarter result with weaker control over costs, although losses were stable and revenues were flat. Third quarter 2021 results: Revenue: US$20.0m (flat on 3Q 2020). Net loss: US$5.47m (flat on 3Q 2020). Major Estimate Revision • Aug 18
Consensus forecasts updated The consensus outlook for 2021 has been updated. 2021 expected loss increased from -US$0.27 to -US$0.33 per share. Revenue forecast unchanged at US$92.2m. Life Sciences industry in the US expected to see average net income growth of 17% next year. Consensus price target broadly unchanged at US$43.00. Share price fell 5.1% to US$28.48 over the past week.